Search results
Showing 7981 to 7995 of 8980 results
We have moved interventional procedures guidance 789 to become HealthTech guidance 723. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
This guidance has been updated and replaced by NICE's highly specialised technologies guidance 34.
This indicator has been updated and replaced by NICE indicator 324.
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued Reference number: GID-TA11261
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
In development Reference number: GID-TA11771 Expected publication date: TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]
In development Reference number: GID-TA11781 Expected publication date: TBC
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
This guidance has been updated and replaced by NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)
This guidance has been updated and replaced by NICE HealthTech guidance 770.
Discontinued Reference number: GID-TA10843
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]
In development Reference number: GID-TA11481 Expected publication date: TBC